Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (0683-014 AM5, EXT1)

This study is ongoing, but not recruiting participants.

Study NCT00128102 Information provided by Merck

First Received: August 5, 2005 Last Updated: August 9, 2011 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

Study Status:	This study is ongoing, but not recruiting participants.
Estimated Study Completion Date:	November 2012
Primary Completion Date:	July 2011 (Final data collection date for primary outcome measure)